Tuberculosis, Hepatitis B and Herpes Zoster in toFacitinib-Treated Patients with Rheumatoid Arthritis

Zhang, Zhuoya; Deng, Wei; Wu, Qizhe; Sun, Lingyun

doi:10.2217/imt-2018-0113

Cited by 29 publications

(22 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Herpes zoster was the most common infection in our cohort. We found a HZ incidence rate similar to that reported from USA and global data; however, we found a lower incidence rate that reported from far East Asia [38]. Most of the patients had HZ in only one dermatome (92%), and 8% of patients with HZ discontinued tofacitinib permanently, similar to current study [21,40].…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience

Bılgın¹,

Ceylan²,

Duran³

et al. 2021

Turk J Med Sci

View full text Add to dashboard Cite

Objective: To assess the real-life efficacy, retention rate and safety data of tofacitinib in rheumatoid arthritis (RA) patients. Method: We analyzed all patients registered in the HURBİO database who received at least 1 dose of tofacitinib. Patients who received at least one dose included in retention analysis, with at least 1 control visit, were included in efficacy and safety analysis. Factors predicting good response at last follow-up visit were analyzed by the logistic regression analysis. Drug retention rates were calculated using the Kaplan-Meier method and predictors of drug retention was determined by Cox proportional hazard model. Adverse events, reasons of switching and discontinuation were also determined. Results: 247 (210, 85.0% female) patients included in the study. Median duration of tofacitinib treatment was 10.2 (20.2) (med, (IQR)) months. 204 (82.6%) patients included in safety and efficacy analysis. 45.6% of patients was in low-disease activity (LDA) state (DAS28-CRP≤3.2). Predictors of LDA were being biologic-navie (aOR 2.53 (1.31-4.88); 95% CI) and RF negativity (aOR 2.14 (1.12-4.07); 95% CI). At 1 year, overall tofacitinib retention rate was 63.9% with no relevant predicting factor. Response and retention rates of tofacitinib were similar in patients with and without concomitant csDMARDs. Treatment failure was the most common cause of discontinuation. The most common infectious and laboratory adverse events were herpes zoster infection (3.9 per 100 patient-years) and elevation in ALT (x3UNL: 9.7 per 100 patient-years), respectively. Conclusion: In conclusion, tofacitinib is an effective-as monotherapy or combination with csDMARDs-and well-tolerated treatment option in Turkish RA patients.

show abstract

Section: Discussionsupporting

confidence: 89%

“…Safety profile including infections and laboratory anomalies of our cohort is consistent with the current literature [21,22,38,39]. We had no HBV reactivation and tuberculosis, which may be due to the strict surveillance and prophylaxis regimen of Turkey.…”

Section: Discussionsupporting

confidence: 87%

Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience

Bılgın¹,

Ceylan²,

Duran³

et al. 2021

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…81 The differential geographical distribution of VZV reactivation in RA patients treated with tofacitinib has been highlighted; Japan and Korea have the highest incidence rates of zoster reactivation equal to 8.1/100 PY (95% CI: 7.0-9.4), followed by Australia, New Zealand and other Asian countries. 66,73 Recently, a post hoc analysis of pooled data confirmed the higher susceptibility to zoster in the Asia-Pacific population compared with the global population [incidence rate (IR) (95% CI) of 0.7 (0.5, 1.0) versus 0. tofacitinib treatment was roughly double the risk observed with the biologics drugs. 86 Several risks factors, including age, sex, use of corticosteroids, history of infections and hospitalisations were reported to be associated with a higher risk of zoster occurrence; the concomitant use of corticosteroids and tofacitinib further doubled the risk of VZV occurrence, independent of MTX use.…”

Section: Hsv and Jakinibs In Inflammatory Rheumatic Diseasesmentioning

confidence: 99%

JAK inhibitors and infections risk: focus on herpes zoster

Sunzini

McInnes

Siebert

2020

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Currently, there is a growing interest in Janus kinase (JAK) intracellular signalling since targeted inhibitors against these pathways are proving effective in the treatment of a range of immune-mediated diseases, such as rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease and atopic dermatitis. In particular, post marketing experience and the increasing development of new pharmacological inhibitors of broad and increasingly selective JAK pathways provide new insights into the JAK pathway role in viral infections as well as their pathogenic role in immune-mediated inflammatory diseases. Herein we provide an overview of the biological role of JAK signalling and its role in immunity against viruses, with particular regard to herpes zoster reactivation. Thereafter, we will discuss the evidence currently available on the principal JAK inhibitors and their association with viral infections.

show abstract

“…Network pharmacology is a systematic approach which emphasizes the integration of systems biology, bioinformatics, and pharmacology [10]. This method interprets the underlying complex relationships among diseases, components and biological systems [50,51]. Nowadays, network pharmacology is deemed to as be a powerful tool which widely applied in effective drug discovery and mechanism study of TCM on complex diseases treatment [52].…”

Section: Discussionmentioning

confidence: 99%

Exploring protective effect of Glycine tabacina aqueous extract against nephrotic syndrome by network pharmacology and experimental verification

Tan

Wang

et al. 2020

Chin Med

View full text Add to dashboard Cite

Background: Glycine tabacina (Labill.) Benth, one of the traditional Chinese herbal medicines, has been used for treatment of nephritis, osteoporosis, rheumatism, and menopausal syndrome. The aim of this study was to illuminate the therapeutic effect and mechanism of Glycine tabacina aqueous extract (GATE) in the treatment of nephrotic syndrome (NS). Methods: UHPLC-DAD-MS/MS was used to analyze the chemical profile of GATE. Adriamycin (ADR)-induced NS mouse model and network pharmacology methods were conducted to explore the protective effect and mechanism of GATE on NS treatment. Results: GATE administration significantly ameliorated symptoms of proteinuria and hyperlipidemia in NS mice, as evidenced by reduced excretion of urine protein and albumin, and decreased plasma levels of total cholesterol and triglyceride. Decreased blood urea nitrogen (BUN) and creatinine levels in NS mice suggested that GATE could prevent renal function decline caused by ADR. GATE treatment also inhibited ADR-induced pathological lesions of renal tissues as indicated by periodic acid Schiff staining. Six flavonoids of GATE were identified by using UHPLC-DAD-MS/ MS. Network pharmacology analysis indicated that the protection of GATE in treating NS might be associated with the regulation of oxidative stress and inflammation. In addition, the in vivo experiment validated that treatment with GATE markedly decreased reactive oxygen species production, malonaldehyde level, and increased superoxide dismutase activity both in plasma and renal tissues. TNF-α level in plasma and protein expression in kidney were significantly decreased in GATE treatment groups. Conclusions: Combination of network pharmacology analysis and experimental verification revealed that GATE exerts anti-NS effect possibly through modulating oxidative stress and inflammation, suggesting the potential application of GATE or its derivatives in the prevention and treatment of NS and other related kidney diseases.

show abstract

Tuberculosis, Hepatitis B and Herpes Zoster in toFacitinib-Treated Patients with Rheumatoid Arthritis

Cited by 29 publications

References 76 publications

Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience

Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience

JAK inhibitors and infections risk: focus on herpes zoster

Exploring protective effect of Glycine tabacina aqueous extract against nephrotic syndrome by network pharmacology and experimental verification

Contact Info

Product

Resources

About